Maitake mushrooms (Grifola frondosa) enhances antibody production in response to influenza vaccination in healthy adult volunteers concurrent with alleviation of common cold symptoms

2023-02-24

Functional Foods in Health and Disease Vol 7, No 7 (2017)

Abstract

We found that continuous Maitake intake raised HI titers against influenza type A virus H1N1 and type B virus, and significantly increased the seroconversion rate for older adults (>60 years of age). Additionally, severe cold symptoms including rhinorrhea and headache were significantly improved by Maitake intake.In this clinical trial, we demonstrated that Maitake intake enhanced antibody production in response to influenza vaccination while simultaneously suppressing multiple common cold symptoms. The current results suggest that Maitake may activate both innate and adaptive immune responses for the prevention of virus infection. In conclusion, we expect that Maitake intake potentiates host defense systems and has a protective effect against influenza virus and other pathogenic viruses and bacteria.

Source:https://ffhdj.com/index.php/ffhd/article/view/363

Cancer Treatement: Complementary & Alternative Medicine (CAM) for Patients: Medicinal Mushrooms (PDQ®)–Patient Version

Medicated mushrooms are mushrooms used as medicine. They have been used for hundreds of years to treat infections, especially in Asia. Today medicinal mushrooms are also used to treat lung disease and cancer.

Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults

Eating L. edodes for 4 weeks resulted in increased ex vivo proliferation of γδ-T (60% more, p < 0.0001) and NK-T (2-fold more, p < 0.0001) cells. Both cell types also demonstrated a greater ability to express activation receptors, suggesting that consuming mushrooms improved cell effector function.

Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages.

Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients

To evaluate the efficacy of Krestin (PSK) as adjuvant treatment after radical radiation therapy (RT) for non-small cell lung cancer (NSCLC), treatment results of 225 patients with NSCLC treated with RT followed by adjuvant administration of PSK between 1976 and 1989 were analyzed. Of these patients, 170 (76%) had squamous cell carcinoma.